Chat with us, powered by LiveChat

Loading...

Computer-Aided Drug Discovery Market, by Type

RA00159

Computer-Aided Drug Discovery Market, by Type (Structure Based Drug Design (SBDD), Ligand-Based Drug Design (LBDD), Sequence-Based Approaches), Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, and Diabetes), End-User (Pharmaceutical Companies, Biotechnology Companies, and Research Institute), and RegionalInsights (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2019–2026

RA00159

Pages: 170

Apr 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Computer-Aided Drug Discovery Market

Global Computer-Aided Drug Discovery Market Insights 2026:

According to research report on computer-aided drug discovery market by Research Dive, Global market forecast will surpass$4,878.5billion by 2026, rising from $1,540.4billion in 2018, at a CAGR of 15.5%. On the basis of region, the North America region held the largest market share accounting for $1,283.1billion in 2026. Asia-Pacific region is expected to boost the global computer-aided drug discovery market size to $1,361.1billion by 2026.

Computer Aided drug discovery accelerates and economizes drug discovery and drugmanufacturing processes; it is considered as an effective strategy. With significant rise in the availability of information on small molecule and biological macromolecule, the efficiency of computer-aided drug discovery has been enhanced and is being extensively applied to almost every phase in drug discovery and manufacturing activities such as detecting targets, validation, lead discovery, and optimization & preclinical tests. Since the last few years, substantial developments have been observed in the computer-aided drug discovery techniques including molecular similarity calculation, de novo design, pharmacophore modeling and mapping, molecular docking, and sequence-based virtual screening. In this research study, we depict a clear understanding of these key computational methods, platforms, and effective applications in this area.

Market Drivers: The growing healthcare expenditure across the globe is anticipated to drive the computer-aided drug discovery market growth

Rising pressure to cut-down healthcare expenses, increasing demand for better quality and cost-effective drugs, growing occurrence of several diseases, increasing number of off-patented drugs, positive results in ongoing clinical experimentations, and growing demand for novel medicines in numerous therapeutic applications for cardiac and oncology disorders are major factors fueling the growth of the industry. However, due to the several obstacles in the development of innovative chemical entities, pharmaceutical industries are in an effort to discover new applications for their prevailing drugs.

The Ligand-based drug design segment held the largest market share in 2018, with a size of $606.9billion, and will further reach $1,878.2billion by 2026, at a CAGR of 15.2%. The Ligand is the process that is being used widely as it is the first stage of developing drugs. Structure-based drug design requires ligand structures for developing the drugs further.

The oncology segment held the largest market value in 2018 accounting for $355.8billion and is expected to reach $1,097.7billion by 2026, growing at a CAGR of 15.1% during the forecast period.The growth is majorly due to the rapid increase in the number of cases that are being registered in the segmentacross the globe. Cardiovascular diseasessegment is expected to hold the largest market share during the forecasted timeframe, accounting for $917.2billion, growing at a CAGR of 15.8% during the forecast period.

The research institutes segment held the largest market value in 2018 accounting for $602.3 billion and is expected to reach $1,873.4 billion by 2026, growing at a CAGR of 15.2% during the forecast period. The growth is majorly due to the number of researches that are being conducted across the globe are majorly done by the research institutes. Pharmaceutical Companies segment is expected to hold the largest market value by 2026, accounting for $1,458.7 billion, growing from $452.9 billion in 2018, at a CAGR of 15.7% during the forecast period.

North America computer-aided drug discovery Market Insights 2026:

North Americaregion held thedominant size in 2018, accounting for $432.9billion and is further anticipated to grow at a CAGR of 14.5% during the forecast period. The growth is owing to the increasingpharmaceutical andbiotechnology industries in this region along with the number of drug development processes taking place in North America region.On the other hand, the Asia-Pacific market is anticipated to experience a swift growth over the forecast period, majorly due to the growing R&D expenditure by pharmaceutical and biotechnology companies. 

Computer-aided drug discoverymarket players includeBOC Sciences, BioDuro, Schrödinger, Aris Pharmaceuticals, Aragen Bioscience, Albany Molecular Research Inc. (AMRI),Charles River, AstraZeneca, Evotec A.G., and Bayers AG. Acquisitions and product development are the key strategies that are being opted by the key industry participants to continue their market position in the regional and global markets.The computer-aided drug discoverymarket players are prominentlyfocusingon technologicaldevelopments, mergers and acquisitions,new product launches, and geographical expansion. These are some of the growth strategies adopted by these companies.

Porter’s Five Forces Analysis for Content Marketing Market:

  • 1.Bargaining Power of Suppliers: The number of key manufacturers in are very limited thus the bargaining power of suppliers is very High.

  • 2.Bargaining Power of Consumers:In this market, the number of consumers is high. 
    The bargaining power of consumers is High.

  • 3.Threat of new entrants: A huge initial investment is required to start up a new company, and thus the threat of new entrants is Low.

  • 4.Threat of substitutes:There are no substitutes present for the computer-aided drug discovery, and thus the threat of substitute is Low.

  • 5.Competitive rivalry in the industry:This market contains a very fewmarket participants. Many of the key players are following similar strategies for the improvement of technologies.
    The competitive rivalry in the industry isHigh.

 

Aspect

Particulars

  Historical Market Estimations

  2018-2019

  Base Year for Market Estimation

  2018

  Forecast timeline for Market Projection

  2019-2026

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Type

  • Structured Based Drug Design (SBDD)

  • Ligand-Based Drug Design (LBDD

  • Sequence-Based Approaches

  Segmentation by Therapeutic Area

  • Oncology

  • Neurology

  • Cardiovascular Disease

  • Respiratory Disease

  • Diabetes

  • Others

  Segmentation by End-use

  • Pharmaceutical Companies

  • Biotechnology Companies

  • Research Laboratories

  Key Countries Covered

U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Latin America, Middle East and Africa

  Key Companies Profiled

  • BOC Sciences

  • BioDuro

  • Schrödinger

  • Aris Pharmaceuticals

  • Aragen Bioscience

  • Albany Molecular Research Inc. (AMRI)

  • Charles River

  • AstraZeneca

  • Evotec A.G.

  • Bayers AG

 


FREQUENTLY ASKED QUESTIONS?
 

A. The global computer-aided drug discovery marketsize was over $1,540.4billion in 2018, and is further anticipated to reach $4,878.5billion by 2026.

A. Albany Molecular Research Inc. (AMRI), BioDuro and Charles River are some of the key players in the global computer-aided drug discovery market.

A. Asia-Pacific possesses great investment opportunities for the investors to witness the most promising growth in the coming years.

A. Asia-Pacificcomputer-aided drug discovery market is projected to grow at 16.1% CAGR during the forecast period.

A. Product development and joint ventures are the key strategies opted by the operating companies in this market.

A. Albany Molecular Research Inc. and Aris Pharmaceuticalsareinvesting more in R&D activities for developing new products and technologies.

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

1.5.Data sources

1.5.1.Primary
1.5.2.Secondary

2.Executive Summary

2.1.360° summary
2.2.Type trends
2.3.Therapeutic Area trends
2.4.End-user trends

3.Market overview

3.1.Market segmentation & definitions
3.2.key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of consumers
3.3.2.Bargaining power of suppliers
3.3.3.Threat of new entrants
3.3.4.Threat of substitutes
3.3.5.Competitive rivalry in the market

3.4.Market dynamics

3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities

3.5.Application landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Market value chain analysis
3.9.Strategic overview

4.Computer-Aided Drug Discovery Market, by Type

4.1.Structure Based Drug Design (SBDD)

4.1.1.Market size and forecast, by region, 2016-2026
4.1.2.Comparative market share analysis, 2018 &2026

4.2.Lignad-Based Drug Design (LBDD)

4.2.1.Market size and forecast, by region, 2016-2026
4.2.2.Comparative market share analysis, 2018 &2026

4.3.Sequence-Based Approaches

4.3.1.Market size and forecast, by region, 2016-2026
4.3.2.Comparative market share analysis, 2018 &2026

5.Computer-Aided Drug Discovery Market, by Therapeutic Area

5.1.Oncology

5.1.1.Market size and forecast, by region, 2016-2026
5.1.2.Comparative market share analysis, 2018 &2026

5.2.Neurology

5.2.1.Market size and forecast, by region, 2016-2026
5.2.2.Comparative market share analysis, 2018 &2026

5.3.Cardiovascular Disease

5.3.1.Market size and forecast, by region, 2016-2026
5.3.2.Comparative market share analysis, 2018 &2026

5.4.Respiratory Disease

5.4.1.Market size and forecast, by region, 2016-2026
5.4.2.Comparative market share analysis, 2018 &2026

5.5.Diabetes

5.5.1.Market size and forecast, by region, 2016-2026
5.5.2.Comparative market share analysis, 2018 &2026

5.6.Others

5.6.1.Market size and forecast, by region, 2016-2026
5.6.2.Comparative market share analysis, 2018 &2026

6.Computer-Aided Drug Discovery Market, by End-user

6.1.Pharmaceutical Companies

6.1.1.Market size and forecast, by region, 2016-2026
6.1.2.Comparative market share analysis, 2018 &2026

6.2.Biotechnology Companies

6.2.1.Market size and forecast, by region, 2016-2026
6.2.2.Comparative market share analysis, 2018 &2026

6.3.Research Institute

6.3.1.Market size and forecast, by region, 2016-2026
6.3.2.Comparative market share analysis, 2018 &2026

7.Computer-Aided Drug Discovery Market, by Region

7.1.North America
7.2.Market size and forecast, by Type, 2016-2026
7.3.Market size and forecast, by Application, 2016-2026
7.4.Market size and forecast, by country, 2016-2026
7.5.Comparative market share analysis, 2018 &2026

7.5.1.U.S.

7.5.1.1.Market size and forecast, by Type, 2016-2026
7.5.1.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.5.1.3.Market size and forecast, by End-user, 2016-2026
7.5.1.4.Comparative market share analysis, 2018 &2026

7.5.2.Canada

7.5.2.1.Market size and forecast, by Type, 2016-2026
7.5.2.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.5.2.3.Market size and forecast, by End-user, 2016-2026
7.5.2.4.Comparative market share analysis, 2018 &2026

7.5.3.Mexico

7.5.3.1.Market size and forecast, by Type, 2016-2026
7.5.3.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.5.3.3.Market size and forecast, by End-user, 2016-2026
7.5.3.4.Comparative market share analysis, 2018 &2026

7.6.Europe

7.6.1.Market size and forecast, by Type, 2016-2026
7.6.2.Market size and forecast, by Application, 2016-2026
7.6.3.Market size and forecast, by country, 2016-2026
7.6.4.Comparative market share analysis, 2018 &2026
7.6.5.UK

7.6.5.1.Market size and forecast, by Type, 2016-2026
7.6.5.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.6.5.3.Market size and forecast, by End-user, 2016-2026
7.6.5.4.Comparative market share analysis, 2018 &2026

7.6.6.Germany

7.6.6.1.Market size and forecast, by Type, 2016-2026
7.6.6.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.6.6.3.Market size and forecast, by End-user, 2016-2026
7.6.6.4.Comparative market share analysis, 2018 &2026

7.6.7.France

7.6.7.1.Market size and forecast, by Type, 2016-2026
7.6.7.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.6.7.3.Market size and forecast, by End-user, 2016-2026
7.6.7.4.Comparative market share analysis, 2018 &2026

7.6.8.Spain

7.6.8.1.Market size and forecast, by Type, 2016-2026
7.6.8.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.6.8.3.Market size and forecast, by End-user, 2016-2026
7.6.8.4.Comparative market share analysis, 2018 &2026

7.6.9.Italy

7.6.9.1.Market size and forecast, by Type, 2016-2026
7.6.9.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.6.9.3.Market size and forecast, by End-user, 2016-2026
7.6.9.4.Comparative market share analysis, 2018 &2026

7.6.10.Rest of Europe

7.6.10.1.Market size and forecast, by Type, 2016-2026
7.6.10.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.6.10.3.Market size and forecast, by End-user, 2016-2026
7.6.10.4.Comparative market share analysis, 2018 &2026

7.7.Asia-Pacific

7.7.1.1.Market size and forecast, by Type, 2016-2026
7.7.1.2.Market size and forecast, by Therapeutic Area, 2016-2026

7.7.2.Market size and forecast, by End-user, 2016-2026
7.7.3.Market size and forecast, by country, 2016-2026
7.7.4.Comparative market share analysis, 2018 &2026

7.7.5.China

7.7.5.1.Market size and forecast, by Type, 2016-2026
7.7.5.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.7.5.3.Market size and forecast, by End-user, 2016-2026
7.7.5.4.Comparative market share analysis, 2018 &2026

7.7.6.Japan

7.7.6.1.Market size and forecast, by Type, 2016-2026
7.7.6.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.7.6.3.Market size and forecast, by End-user, 2016-2026
7.7.6.4.Comparative market share analysis, 2018 &2026

7.7.7.India

7.7.7.1.Market size and forecast, by Type, 2016-2026
7.7.7.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.7.7.3.Market size and forecast, by End-user, 2016-2026
7.7.7.4.Comparative market share analysis, 2018 &2026

7.7.8.Australia

7.7.8.1.Market size and forecast, by Type, 2016-2026
7.7.8.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.7.8.3.Market size and forecast, by End-user, 2016-2026
7.7.8.4.Comparative market share analysis, 2018 &2026

7.7.9.South Korea

7.7.9.1.Market size and forecast, by Type, 2016-2026
7.7.9.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.7.9.3.Market size and forecast, by End-user, 2016-2026
7.7.9.4.Comparative market share analysis, 2018 &2026

7.7.10.Rest of Asia-Pacific

7.7.10.1.Market size and forecast, by Type, 2016-2026
7.7.10.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.7.10.3.Market size and forecast, by End-user, 2016-2026
7.7.10.4.Comparative market share analysis, 2018 &2026

7.8.LAMEA

7.8.1.1.Market size and forecast, by Type, 2016-2026
7.8.1.2.Market size and forecast, by Therapeutic Area, 2016-2026

7.8.2.Market size and forecast, by End-user, 2016-2026
7.8.3.Market size and forecast, by country, 2016-2026
7.8.4.Comparative market share analysis, 2018 &2026
7.8.5.Latin America

7.8.5.1.Market size and forecast, by Type, 2016-2026
7.8.5.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.8.5.3.Market size and forecast, by End-user, 2016-2026
7.8.5.4.Comparative market share analysis, 2018 &2026

7.8.6.Middle East

7.8.6.1.Market size and forecast, by Type, 2016-2026
7.8.6.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.8.6.3.Market size and forecast, by End-user, 2016-2026
7.8.6.4.Comparative market share analysis, 2018 &2026

7.8.7.Africa

7.8.7.1.Market size and forecast, by Type, 2016-2026
7.8.7.2.Market size and forecast, by Therapeutic Area, 2016-2026
7.8.7.3.Market size and forecast, by End-user, 2016-2026
7.8.7.4.Comparative market share analysis, 2018 &2026

1.Company profiles

1.1.InfineonTechnologies

1.1.1.Business overview
1.1.2.Financial performance
1.1.3.Type portfolio
1.1.4.Recent strategic moves & developments
1.1.5.SWOT analysis

1.2.Mitsubishi

1.2.1.Business overview
1.2.2.Financial performance
1.2.3.Type portfolio
1.2.4.Recent strategic moves & developments
1.2.5.SWOT analysis

1.3. Fuji Electric

1.3.1.Business overview
1.3.2.Financial performance
1.3.3.Type portfolio
1.3.4.Recent strategic moves & developments
1.3.5.SWOT analysis

1.4.Semikron

1.4.1.Business overview
1.4.2.Financial performance
1.4.3.Type portfolio
1.4.4.Recent strategic moves & developments
1.4.5.SWOT analysis

1.5.ON Semiconductors

1.5.1.Business overview
1.5.2.Financial performance
1.5.3.Type portfolio
1.5.4.Recent strategic moves & developments
1.5.5.SWOT analysis

1.6. FairchildSemiconductor

1.6.1.Business overview
1.6.2.Financial performance
1.6.3.Type portfolio
1.6.4.Recent strategic moves & developments
1.6.5.SWOT analysis

1.7.Texas Instruments Incorporated

1.7.1.Business overview
1.7.2.Financial performance
1.7.3.Type portfolio
1.7.4.Recent strategic moves & developments
1.7.5.SWOT analysis

1.8.STMicroelectronics

1.8.1.Business overview
1.8.2.Financial performance
1.8.3.Type portfolio
1.8.4.Recent strategic moves & developments
1.8.5.SWOT analysis

1.9.IXYS

1.9.1.Business overview
1.9.2.Financial performance
1.9.3.Type portfolio
1.9.4.Recent strategic moves & developments
1.9.5.SWOT analysis

1.10.Toshiba

1.10.1.Business overview
1.10.2.Financial performance
1.10.3.Type portfolio
1.10.4.Recent strategic moves & developments
1.10.5.SWOT analysis

There is no deficit of antibiotic drugs in the market and these drugs have customarilybeenused for a much longer time compared to most of the other drugs. However, from time unknown humans have been fighting an unseen war with strange viruses and bacteria which is never going to end.
This, in some way or other, is contributing to the rise of antibiotics drug resistance which leads to the need for new antibiotics. 

The computer-aided drug design (CADD) is amalgamated with wet-lab techniques to clarify the mechanism of drug resistance, to search for new antibiotic targets and to design new and original antibiotics for both existing and new targets. CADD process can produce an atomic level structure-activity relationship (SAR) which is used to facilitate the drug design process thuscurtailingboth time and costs.

Factors impacting the market

It is the significant rise in the availability of information and data related to small molecule and biological macromoleculethat has enhanced the efficiency of computer-aided drug discovery. This extensive resource has been applied to almost every phase in the drug discovery process and manufacturing activities such as validation, lead discovery, detecting targets, and optimization and preclinical tests. In recent years, successive developments have been observed in the computer-aided drug discovery techniques. These techniques includede novo design,molecular similarity calculation, molecular docking,pharmacophore modeling and mapping, and sequence-based virtual screening.

In addition, the increasing healthcare expenditure across the globe is another factor enhancing the growth of the global market of computer-aided drug discovery. Someother factors fueling the market include the rising demand to diminish healthcare expenses, affordable and good-quality drugs, frequent occurrence of several known and unknown diseases, positive results in ongoing clinical experimentations, increasing number of off-patented drugs, and growing claim for brand new medicines for cardiac and oncology disorders. 

Recent Developments in the Global Market

According to a recent report , the leading players of the global computer-aided drug discovery market are Bayers AG,BioDuro, BOC Sciences,Schrödinger, Aragen Bioscience,Aris Pharmaceuticals, Charles River,Albany Molecular Research Inc. (AMRI), Evotec A.G., and AstraZeneca. 

These market players are adopting several strategies including new technology, new product launches, current technology upgradation, and merger and acquisition to gain highest employee communication software market size. 

Recently, a virtual reality (VR) platform developed by researchers at the University of Bristol has permitted the computational scientists, chemists, and structural biologists to collaboratively design molecules. “It’s bringing human intuition to bear in a new way,” asserts Adrian Mulholland, a professor in the Centre for Computational Chemistry of the University of Bristol.

Purchase Options

Enquire To Buy

Personalize this research

  • Triangulate with your own data
  • Get Data as per your format and defination
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed